MedPath

Evaluation of the effect of oral prolive on liver function in patients with major and intermediate thalassemia

Phase 3
Recruiting
Conditions
Major and intermedia thallassemia.
Other disorders of blood and blood-forming organs in diseases classified elsewhere
Registration Number
IRCT20191010045050N1
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

All patients with beta thalassemia major and intermedia over 5 years

Exclusion Criteria

Patients not willing to participate in the study
Malignancy
Liver dysfunction

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
iver enzyme. Timepoint: Before the intervention and after, every one month to six months. Method of measurement: Laboratory.;Total Billirubin and Total protein. Timepoint: Before the intervention and after, every one month to six months. Method of measurement: Laboratory.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath